E3 ligase Ligand 1 dihydrochloride

 Cat No.: BP-200028 4.5  

E3 ligase Ligand 1 dihydrochloride is a high-purity small molecule designed for use as an E3 ligase ligand in PROTAC (Proteolysis Targeting Chimera) drug discovery research. As a dedicated E3 ligase ligand, this compound facilitates the recruitment of E3 ubiquitin ligase complexes, enabling targeted degradation of disease-related proteins. The dihydrochloride salt form enhances solubility and stability, making it suitable for both in vitro and cellular PROTAC applications. E3 ligase Ligand 1 is ideal for researchers developing novel bifunctional molecules for the selective and efficient removal of target proteins, thereby accelerating advances in protein degradation therapeutics.

E3 ligase Ligand 1 dihydrochloride

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Ligand for E3 Ligase
Molecular Formula
C23H34Cl2N4O3S
Molecular Weight
517.51

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping
Room temperature in continental US; may vary elsewhere
Synonyms
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide;dihydrochloride
InChI Key
YTJDUDNKHHNDRD-ARZBPYMHSA-N
InChI
InChI=1S/C23H32N4O3S.2ClH/c1-13(15-6-8-16(9-7-15)19-14(2)25-12-31-19)26-21(29)18-10-17(28)11-27(18)22(30)20(24)23(3,4)5;;/h6-9,12-13,17-18,20,28H,10-11,24H2,1-5H3,(H,26,29);2*1H/t13-,17+,18-,20+;;/m0../s1
Canonical SMILES
CC1=C(SC=N1)C2=CC=C(C=C2)C(C)NC(=O)C3CC(CN3C(=O)C(C(C)(C)C)N)O.Cl.Cl

Background Introduction

E3 ligase Ligand 1 dihydrochloride is a small-molecule compound specifically designed for application as an E3 ubiquitin ligase recruiter in PROTAC (Proteolysis Targeting Chimera) technology. With its highly selective binding affinity to particular E3 ligase complexes, this ligand serves as a critical building block for next-generation protein degradation tools. The dihydrochloride salt form enhances its solubility and handling properties, making it ideal for chemical biology, medicinal chemistry, and drug discovery workflows.

Mechanism

E3 ligase Ligand 1 dihydrochloride functions as a molecular adaptor that binds selectively to a specific E3 ubiquitin ligase, such as VHL, CRBN, or other engineered E3s. In the context of PROTACs, this ligand is chemically linked to a target protein ligand, forming a bifunctional molecule. Upon introduction into the cellular environment, the ligand facilitates proximity between the target protein and the E3 ligase complex, resulting in the ubiquitination of the target, followed by its recognition and degradation by the 26S proteasome. The dihydrochloride formulation ensures enhanced solubility for efficient conjugation and bioactivity in aqueous and physiological environments.

Applications

E3 ligase Ligand 1 dihydrochloride is an essential component in the design and synthesis of PROTACs and other targeted protein degradation strategies. Its stable and soluble form allows for effective conjugation with various target protein ligands, enabling the construction of customizable degraders for research and therapeutic development. Key applications include:

• Design and synthesis of E3 ligase-recruiting arms in bifunctional PROTAC molecules
• Development of tool compounds for validating protein targets via induced degradation
• Structure-activity relationship (SAR) studies for optimizing targeted protein degrader efficacy
• Academic, biotech, and pharmaceutical research into novel therapeutic modalities
• Supporting custom synthesis projects for specialized degrader discovery and production
• High-purity compound verified by HPLC, NMR, and LC-MS
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• High-affinity binding to E3 ligase improves targeted protein degradation efficiency in PROTAC development.
• Dihydrochloride salt form enhances compound solubility and stability for easier handling in synthetic applications.
1. RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis
Huazhi Zhang, Zhihui Cui, Du Cheng, Yanyun Du, Xiaoli Guo, Ru Gao, Jianwen Chen, Wanwei Sun, Ruirui He, Xiaojian Ma, Qianwen Peng, Bradley N Martin, Wei Yan, Yueguang Rong, Chenhui Wang Autophagy. 2021 Oct;17(10):3030-3047.doi: 10.1080/15548627.2020.1851496.Epub 2020 Dec 17.
Although genome-wide association studies have identified the gene RNF186 encoding an E3 ubiquitin-protein ligase as conferring susceptibility to ulcerative colitis, the exact function of this protein remains unclear. In the present study, we demonstrate an important role for RNF186 in macroautophagy/autophagy activation in colonic epithelial cells and intestinal homeostasis. Mechanistically, RNF186 acts as an E3 ubiquitin-protein ligase for EPHB2 and regulates the ubiquitination of EPHB2. Upon stimulation by ligand EFNB1 (ephrin B1), EPHB2 is ubiquitinated by RNF186 at Lys892, and further recruits MAP1LC3B for autophagy. Compared to control mice, rnf186-/- and ephb2-/- mice have a more severe phenotype in the DSS-induced colitis model, which is due to a defect in autophagy in colon epithelial cells. More importantly, treatment with ephrin-B1-Fc recombinant protein effectively relieves DSS-induced mouse colitis, which suggests that ephrin-B1-Fc may be a potential therapy for human inflammatory bowel diseases.Abbreviations: ACTB: actin beta; ATG5: autophagy related 5; ATG16L1: autophagy related 16 like 1; ATP: adenosine triphosphate; Cas9: CRISPR associated protein 9; CD: Crohn disease; CQ: chloroquine; Csf2: colony stimulating factor 2; Cxcl1: c-x-c motif chemokine ligand 1; DMSO: dimethyl sulfoxide; DSS: dextran sodium sulfate; EFNB1: ephrin B1; EPHB2: EPH receptor B2; EPHB3: EPH receptor B3; EPHB2K788R: lysine 788 mutated to arginine in EPHB2; EPHB2K892R: lysine 892 mutated to arginine in EPHB2; ER: endoplasmic reticulum; FITC: fluorescein isothiocyanate; GFP: green fluorescent protein; GWAS: genome-wide association studies; HRP: horseradish peroxidase; HSPA5/BiP: heat shock protein family A (Hsp70) member 5; IBD: inflammatory bowel diseases; Il1b: interleukin 1 beta; Il6: interleukin 6; IRGM:immunity related GTPase M; i.p.: intraperitoneally; IPP: inorganic pyrophosphatase; KD: knockdown; KO: knockout; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MTOR: mechanistic target of rapamycin kinase; NOD2: nucleotide binding oligomerization domain containing 2; PI3K: phosphoinositide 3-kinase; PtdIns3K: class III phosphatidylinositol 3-kinase; RNF186: ring finger protein 186; RNF186A64T: alanine 64 mutated to threonine in RNF186; RNF186R179X: arginine 179 mutated to X in RNF186; RPS6: ribosomal protein S6; Tnf: tumor necrosis factor; SQSTM1: sequestosome 1; Ub: ubiquitin; UBE2D2: ubiquitin conjugating enzyme E2 D2; UBE2H: ubiquitin conjugating enzyme E2 H; UBE2K: ubiquitin conjugating enzyme E2 K; UBE2N: ubiquitin conjugating enzyme E2 N; UC: ulcerative colitis; ULK1:unc-51 like autophagy activating kinase 1; WT: wild type.
2. Receptor control by membrane-tethered ubiquitin ligases in development and tissue homeostasis
Andres M Lebensohn, J Fernando Bazan, Rajat Rohatgi Curr Top Dev Biol. 2022;150:25-89.doi: 10.1016/bs.ctdb.2022.03.003.Epub 2022 Jun 11.
Paracrine cell-cell communication is central to all developmental processes, ranging from cell diversification to patterning and morphogenesis. Precise calibration of signaling strength is essential for the fidelity of tissue formation during embryogenesis and tissue maintenance in adults. Membrane-tethered ubiquitin ligases can control the sensitivity of target cells to secreted ligands by regulating the abundance of signaling receptors at the cell surface. We discuss two examples of this emerging concept in signaling: (1) the transmembrane ubiquitin ligases ZNRF3 and RNF43 that regulate WNT and bone morphogenetic protein receptor abundance in response to R-spondin ligands and (2) the membrane-recruited ubiquitin ligase MGRN1 that controls Hedgehog and melanocortin receptor abundance. We focus on the mechanistic logic of these systems, illustrated by structural and protein interaction models enabled by AlphaFold. We suggest that membrane-tethered ubiquitin ligases play a widespread role in remodeling the cell surface proteome to control responses to extracellular ligands in diverse biological processes.
3. CRT-1/calreticulin and the E3 ligase EEL-1/HUWE1 control hemidesmosome maturation in C. elegans development
Hala Zahreddine, Huimin Zhang, Marie Diogon, Yasuko Nagamatsu, Michel Labouesse Curr Biol. 2010 Feb 23;20(4):322-7.doi: 10.1016/j.cub.2009.12.061.Epub 2010 Feb 11.
Hemidesmosomes connect the extracellular matrix (ECM) to intermediate filaments through ECM receptors and plakins (plectin and BPAG1e). They affect tissue integrity, wound healing, and carcinoma invasion. Although biochemical and time-lapse studies indicate that alpha6beta4-integrin (ECM receptor) and plectin play a central role in modulating hemidesmosome disassembly, the mechanisms controlling hemidesmosome biogenesis in vivo remain poorly understood. The nematode C. elegans provides a powerful genetic model to address this issue. We performed a genome-wide RNA interference screen in C. elegans, searching for genes that decrease the viability of a weak VAB-10A/plakin mutant. We identified 14 genes that have human homologs with predicted roles in different cellular processes. We further characterized two genes encoding the chaperone CRT-1/calreticulin and the HECT domain E3 ubiquitin ligase EEL-1/HUWE1. CRT-1 controls by as little as 2-fold the abundance of UNC-52/perlecan, an essential hemidesmosome ECM ligand. Likewise, EEL-1 fine tunes by 2-fold the abundance of myotactin, the putative hemidesmosome ECM receptor. CRT-1 and EEL-1 activities, and by extension other genes identified in our screen, are essential during embryonic development to enable hemidesmosomes exposed to mechanical tension to mature into a tension-resistant form. Our findings should help understand how hemidesmosome dynamics are regulated in vertebrate systems.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket